Introduction
============

Chronic myeloid leukemia (CML) is a malignant disorder of the stem cell due to reciprocal balanced translocation of genetic material between the long arms of chromosomes 9 and 22 t (9; 22) (q34; q11).[@b1-mjhid-9-1-e2017062] The translocation causes the production of a new hybrid gene (BCR/ABL) that codes for a 210 Kb cytoplasmic protein (P210), which by autophosphorylation activates some signaling pathways involved in cell proliferation, maturation, apoptosis, and adhesion, leading to the malignant cell transformation.[@b2-mjhid-9-1-e2017062] Imatinib mesylate (Glivec®/Gleevec®) is the standard first-line therapy for the treatment of CML due to its high hematologic, cytogenetic, and molecular response rates and favorable long-term safety profile.[@b3-mjhid-9-1-e2017062] It has been some years since TKI were introduced in CML therapeutic strategy either in case of intolerance or resistance to Imatinib or as a first line drug when it was observed that it has a more rapid and profound molecular response when compared to Imatinib.[@b4-mjhid-9-1-e2017062] More recently a third generation of TKI has been available in case of intolerance or resistance to TKI of the second generation and especially for patients who developed the resistance with a mutation T315I.[@b5-mjhid-9-1-e2017062] Due to the fundamental role of Imatinib in first-line therapy of CML, as well as the high cost of Imatinib, which is not affordable in some countries, a copy preparation, consisting of the alpha crystal form of imatinib, has become commercially available under the name 'imatib' (CIPLA-India). It is currently available at a markedly reduced price in several countries. The manufacturer of imatib (IM, copy) lists the product as being 'comparable' to imatinib mesylate.[@b6-mjhid-9-1-e2017062] However, the safety and efficacy of these molecules have not been widely assessed and for which patient data are limited, and the safety and efficiency of this drug have not been demonstrated yet in a randomized clinical trial.

In Algeria 'imatib' (CIPLA-India) was introduced in 2006, but no study has been published yet in the North Africa region regarding the response and the outcome of this copy in CML patients. The goal of this multicenter study is to characterize newly adult CML in the western region of Algeria and to assess the effectiveness and safety of imatib as frontline therapy for patients with CML.

Patients and Methods
====================

In Algeria, the incidence of CML was 0.53/100,000 inhabitants with a prevalence of 1030 cases in 2014. The median age is 48 years (03--90) with a peak incidence in the age group (45--49 years) and slight male predominance (sex ratio: 1,2).

Patients' characteristics
-------------------------

The study was carried out in all the 7 hematological services of university hospitals, in the western Algeria and data were collected using electronic medical records from patients' clinic visits. All patients aged over 15 years with *de novo* CML were included.

It is a longitudinal study, multicentric and retrospective. Patients, who were diagnosed to be suffering from CML between 1^st^ January 2007 and 31^st^ December 2014, were selected for data analysis. In all patients, the diagnosis of CML was confirmed by morphologic review of peripheral blood (PB) and by RT-PCR based BCR-ABL analysis (Applied Biosystems 7500 Real-time PCR system).[@b7-mjhid-9-1-e2017062] Staging and evaluations of response were determined according to the current European LeukemiaNet (ELN) recommendations.[@b8-mjhid-9-1-e2017062] The prognosis of CML patients in chronic phase was determined by either Sokal and/or EUTOS prognostic scoring systems at initial presentation, using European LeukemiaNet calculator.[@b9-mjhid-9-1-e2017062] Patients with acceleration and blastic phase were not included in our study. All patients received a copy preparation, consisting of the alpha crystal form of imatinib, (Imatib) at an oral dose of 400 mg daily and monitored for tolerance and side effects according to the ELN recommendations adapted to our conditions and capabilities in Algeria. Doses were reduced in the presence of grade 3--4 thrombocytopenia or grade 3--4 neutropenia. Wherever it was possible the dose was maintained above 300 mg/day. Patients were treated as long as they continued to respond.

Response assessment
-------------------

All patients were assessed for response to treatment by weekly physical examination, full blood count, and biochemistry for the first 6-weeks of treatment and were assessed every 3 months during their follow-up. During the treatment, quantitative, real-time PCR (RQ-PCR) for the determination of BCR/ABL1 transcripts level using the international scale, has been performed every 3 months until achievement of an MMR, then every 3 to 6 months. The complete hematologic response (CHR) at 03 months and molecular response at 03, 06, 12, 18, 24 months and more according to capabilities. At 03 months and/or 6 months we looked for a BCR/ABL1 rate \<10%. At 12 months we looked for a major molecular response (MMR), defined by BCR/ABL1 ratio lower than 0,1% according to the ELN. A ratio between 0,1 to 1% is considered a good response according to GAT-LMC (the CML study Algerian group), so the Imatinib treatment is continued.

Statistical Analysis
--------------------

The statistical analysis used the calculation of averages and the Khi2 test. Overall survival (OS) was calculated from the time of diagnosis to the date of death or last follow-up. The Kaplan--Meier method was used to estimate survival rates and the log-rank test to determine differences between subgroups. For all tests, a p-value of less than 0.05 was considered statistically significant. Statistical calculations were performed using the software package SPSS 20 (SPSS, Inc., Chicago, IL). The median follow-up of patients in December 2014 is 46 months (13--107 months).

Results
=======

From January 2007 to December 2014, 387 patients with CML were treated with imatib. Among them 355 patients are evaluable. The clinical characteristics of patients are shown in [Table 1](#t1-mjhid-9-1-e2017062){ref-type="table"}. The median age of patients was 48 years (range: 16--85 years), 182 patients were male, and 173 were female (sex ratio= 1,05). The median time from diagnosis to treatment was 3 months (0.1--4). Splenomegaly was the most common clinical feature present in 86% of patients. At diagnosis, the median number of white blood cells (WBC) was 346 G/L (range: 78--588 G/L). The prognostic classification, according to the Sokal score, found a low risk in 18%, intermediate risk in 40% and a high risk in 42%. The Eutos score is less than 87 in 75,5% and more than 87 in 24,5%. A CHR at 03 months was found in 295 patients (83%) without any significant differences considering either the Sokal groups \[72% in low-risk group, 78% in intermediate risk group, and 69% in high-risk group (p=0.26)\] or the EUTOS score \[81% in low-risk group, and 70% in high-risk group (p=0.08)\]. A major molecular response (MMR) was achieved at six months (M6), M9, M12, M18, and M24 in 21%, 38%, 35%, 51% and 67% respectively and 34% of patients achieved a complete molecular response (CMR). The 5-year overall survival (OS) rate was 83% ([Figure 1](#f1-mjhid-9-1-e2017062){ref-type="fig"}). According to Sokal groups, we observed a significant difference in OS with at 5-years, 93% for low-risk group, 84% for intermediate risk group and 78% in high-risk group (p = 0.009) ([Figure 2](#f2-mjhid-9-1-e2017062){ref-type="fig"}). When patients were stratified according to EUTOS risk classification, a significant difference in OS rates was observed (p=0.02), and the 5-year OS rates for low, and high-risk groups were 90% and 74% respectively ([Figure 3](#f3-mjhid-9-1-e2017062){ref-type="fig"}).

Side effects of imatib (copy) in this study are shown in [Table 2](#t2-mjhid-9-1-e2017062){ref-type="table"}, and no adverse effects related deaths have occurred. At a median follow-up duration of at least 48 months (12--84 months), 81% of patients are alive and are still taking imatib, 10% of patients relapsed among them 50% because of low adherence, 42% because of resistance and only 8% developed intolerance to imatib. 9% of patients died after developing blastic phase disease. 6% of patients discontinued their follow-up, and 4% of patients died due to other reasons.

Discussion
==========

CML constitutes the most common myeloproliferative disorder in Algeria. The incidence of CML was 0.53/100,000 inhabitants with a prevalence of 1030 cases in 2014 in the country, with 472 newly cases/year.[@b10-mjhid-9-1-e2017062] The median age is 48 years with a peak incidence in the age group (45--49 years) and slight male predominance (sex ratio: 1,2).[@b10-mjhid-9-1-e2017062] The median age of patients with CML in Algeria and other African countries with a similar demographic pattern is over 40 years and lower than that reported in Europe and United States.[@b11-mjhid-9-1-e2017062]--[@b12-mjhid-9-1-e2017062]

Our multicenter study of patients with newly diagnosed CML is unique in Northern Africa. Regarding the clinical and biological feature, CML of Algerian patients seems to be frequently aggressive with anemia and a massive splenomegaly associated in a majority of cases with a high-risk Sokal.

After ITK therapy, results were very well known and described regarding Glivec®/Gleevec® used in multiple clinical trials showing cumulative OS rates of 86%, after 7-years of follow-up.[@b3-mjhid-9-1-e2017062]

In low-income countries like Algeria, such expensive treatment is not available, and physicians in charge of adult CML patients are obliged to use a copy form, which could appear as less effective therapy in this setting. To our knowledge, there are only a few data regarding generic forms or imatib for Algerian patients with CML. A.H. Goubran,[@b13-mjhid-9-1-e2017062] Z. Chouffai,[@b14-mjhid-9-1-e2017062] I.A. Asfour[@b15-mjhid-9-1-e2017062] and M. Mattar[@b16-mjhid-9-1-e2017062] published only case reports and showed outcomes failure with Imatib copy. Ostojic A, showed that when taken at equivalent doses, imatinib generics are bioequivalent, comparable in clinical efficacy and have the potential for substantial savings in the treatment cost for CML.[@b18-mjhid-9-1-e2017062] In a prospective, multicenter clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with CP of CML in China, the authors showed that among 107 patients at 3-month, the CHR rate was 98.1% (105/107). The BCR-ABL transcript was ≤10% in 77/106 patients (72, 6%), 11 of them (10, 4%) achieved MMR (BCR-ABL≤0,1%). At 6-month, the CHR rate was 100%; BCR-ABL was ≤1% in 68,5%, and 33% of them achieved MMR. Grade 3 leukopenia, thrombocytopenia and anemia rates were 19,5%, 23% and 13,8%, respectively. No patient experienced grade 4 non-hematologic toxicity. No adverse effects related deaths have occurred.[@b18-mjhid-9-1-e2017062]

Our study is the first study concerning a large cohort of patients receiving Imatib for CML and which has analyzed the safety, efficacy, OS at short, medium and long-term. With a median follow-up of 46 months (range: 13--107), we found 83% of CHR with 67% of MMR at 2 years, and 34% of CMR. The IRIS trial at 7-years has demonstrated better overall survival rate of 86%.[@b19-mjhid-9-1-e2017062] At 5-years and 9-years, OS in our study was 83% and 67% respectively. Respect to literature data we observed a larger group of patients (17%) who have never achieved a CHR probably related to the existence of higher proportion (42%) with high-risk Sokal score and it was demonstrated that there was a relationship between prognosis and disease response. In parallel, the delayed diagnosis is one of the arguments in favor of the disease extension.

Side effects of imatib in our study were similar to those reported previously for the imatinib mesylate treatment study and only 8% of patients showed intolerance to imatib and switch to the second generation of ITK. There was a previous report from Canada with similar conclusions about the efficacy and tolerability of generic imatinib, although they used a different source of generic imatinib from our study.[@b20-mjhid-9-1-e2017062]

Scarce compliance in CML patients treated with BCR-ABL inhibitors is common and associated with critical outcomes. Poor adherence to therapy was associated with a negative impact on both clinical and economic outcomes.[@b21-mjhid-9-1-e2017062] In our study, more than 15% of patients presented poor adherence to CML treatment, and they had a lower CHR response at 3 months and MMR at 6 months. The estimated 5-year OS in our patients was comparable to the 72% reported in the study from Côte d'Ivoire[@b22-mjhid-9-1-e2017062] and the 80% in the study from Nepal,[@b23-mjhid-9-1-e2017062] whom patients were treated with imatinib mesylate (Gliveec®).

Conclusions
===========

This study reflects a real-world experience by treating patients with CML in a developing country and thus sheds light on differences in this population compared to Western countries. A higher proportion of patients were diagnosed at later stages of CP compared to reports from Western countries, and that may impact response rates seen with frontline imatib. Imatib (copy) is effective and safe in treating patients with CML in chronic phase and proves to have a durable outcome. To our knowledge, this is the first study reporting the response to imatib (copy) in an Algerian population.
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###### 

Pretreatment characteristics of the study population with CML.

  Patients number, N                                                                       355
  ---------------------------------------------------------------------------------------- ------------------
  **Gender male, N (%)**                                                                   182 (51)
  **Age, years, median (range)**                                                           48 (16--85)
  **Spleen, cm**[a](#tfn1-mjhid-9-1-e2017062){ref-type="table-fn"}**, median (range)**     13.0 (0--29.0)
  **Palpable spleen, N (%)**                                                               305 (86)
  **Blasts**[b](#tfn2-mjhid-9-1-e2017062){ref-type="table-fn"}**, %, median (range)**      3.0 (0--12.5)
  **Basophils**[b](#tfn2-mjhid-9-1-e2017062){ref-type="table-fn"}**, %, median (range)**   3.7 (0--13.5)
  **PLT count,** G/L**; median (range)**                                                   393 (98--1.360)
  **Hemoglobin, g/dl, median (range)**                                                     11.5 (6.0--16.8)
  **WBC count,** G/L**; median (range)**                                                   346 (78--588)
  **Sokal score, (%)**                                                                     
   **Low**                                                                                 \(18\)
   **Intermediate**                                                                        \(40\)
   **High**                                                                                \(42\)
  **EUTOS score, (%)**                                                                     
   **Low**                                                                                 (75.5)
   **High**                                                                                (24.5)

Maximum distance below the costal margin, assessed by manual palpation.

Percentage in peripheral blood.

###### 

Incidence of grade 3--4 side effects with imatib copy therapy.

  Toxicity                         Grades 3--4 (%)
  -------------------------------- -----------------
  **Non Hematologic toxicities**   
  **Muscle cramps**                \(8\)
  **Nausea and diarrhea**          \(6\)
  **Skin rash**                    \(13\)
  **Bone or joint aches**          \(27\)
  **Liver toxicity**               \(10\)
  **Hematologic toxicities**       
  **Neutropenia**                  \(16\)
  **Thrombocytopenia**             \(25\)
  **Anemia**                       \(3\)
